ARTICLE | Company News
Beactica, AstraZeneca deal
November 19, 2007 8:00 AM UTC
Beactica will use its fragment-based technology to characterize compounds from AZN's Arrow Therapeutics Ltd. subsidiary against an undisclosed antiviral target. Arrow will own resulting IP. Further t...